

PATIENT ORGANIZATION SERVICE AGREEMENT

Made as of October 31, 2025, by and between

Atopisk Eksem Forening / Eksemforeningen, a legal entity having its registered address at c/o Lone Grøn Laursen, Hvidovrevej 108, 1. tv., 2650 Hvidovre, Denmark provided with Danish CVR 33736665 (hereinafter called the “**Patient Organization**”).

and

Almirall Aps (hereinafter “**Almirall**”), a Company organised and existing pursuant to the Laws of Denmark, and having its domicile at Vandtårnsvej 77, 2860 Søborg, Denmark

WITNESSETH

I. Almirall is a pharmaceutical company engaged in the project to evaluate wellbeing, quality of life, and socioeconomic impact of Nordic AD patients, focusing on undertreatment and patients "falling through the net" across Norway, Denmark, and Sweden (hereinafter, the “**Project**”).

II. The Patient Organization has broad and certified knowledge of this field.

III. Almirall is interested in engaging in a collaboration with the Patient Organization, and the Patient Organization is interested in being contracted by Almirall, for the purpose of collaborating in the context of the Project, to the extent and according to the conditions stated in this Agreement (hereinafter the “**Services**”).

NOW, THEREFORE, the parties hereto agree as follows

TERMS AND CONDITIONS

1.- Scope and duration of the Services

- Scientific field: Atopic Dermatitis
- Dates: November 2025 – December 2027
- Description of the Service:

Almirall conducts the Wellbeing and Quality of Life Survey among Nordic patients with Atopic Dermatitis. The survey is developed and conducted in collaboration with the Patient Organization.

The Patient Organization receives no financial compensation for this collaboration, but actively participates in the implementation of the project and has the right to provide input and use the results of the survey. Almirall will cover costs related to notices/advertisements to include participants in the survey.

The Patient Organization will help send out information about a web-based survey prepared jointly to its members and other patients with atopic dermatitis.

In return, the Patient Organization can use the results and the outcome of the survey, provided that it appears that the project has been carried out in collaboration with Almirall Aps and NHG Denmark as technical supplier.

The Patient Organization can provide input on the design of the project, the report and any publication and presentation.

The Patient Organization is included in the list of authors for any publication and presentation of the results. The Patient Organization can submit abstracts for presentation to various congresses or other forums with a focus on patient participation. The Patient

Organization can present results, provided that Almirall Aps are involved as authors and are given the opportunity to provide input before submission and presentation.

After publication, The Patient Organization can reproduce the results of the survey and communicate the results orally or in writing.

The scope of this Agreement consists of the performance by the Patient Organization of the non-promotional Services defined under the terms and conditions of this Agreement. The Services shall be rendered on the basis of the experience and knowledge of the Patient Organization, who will mainly consider the objectives of the Services as confirmed by Almirall, as well as the information and data made available to the Patient Organization by Almirall.

For the avoidance of any doubt, the Patient Organization shall refrain from performing any action that may consist of a direct or indirect promotion of any particular medicinal product, device or service during the course of the Service.

2.- Compensation for the Services

1. The Patient Organization will not receive any economical compensation for the performance of the Services. However, Almirall shall book and/or reimburse to the Patient Organization any reasonable travel, meal and accommodation expenses which are strictly necessary for the performance of the Services, if any, against delivery to Almirall of a copy of the corresponding supporting documents, and in any case up to the maximum global amount previously agreed upon. Where expenses have been incurred, reimbursement will be made on provision of satisfactory invoices and itemised original receipts clearly detailing the nature of each expense incurred which must be submitted to Almirall within 30 days of the event. Failure to do so may result in non-payment

2. The Parties agree to comply at all times with the EFPIA Code and any other deontological code and/or standard of the pharmaceutical industry, either international or local, including but not limited to Events and Hospitality rules stated in those regulations.

3. The payment of the corresponding amount according to paragraph 1 above shall be paid to the Patient Organization upon the complete performance of the Services, by bank transfer, within thirty (30) days from receipt of the corresponding invoice and adding when applicable the VAT at the rate corresponding to the date of issue of the invoice.

Bank account owner	Eksempforeningen
IBAN	DK8350370001224283

3.-Term of the Services

1. This Agreement shall continue in force until the complete performance of the Services in accordance with the terms and conditions of this Agreement.

2. Upon any breach or other defect of performance by either party of any provision of this Agreement, the other party may terminate this Agreement by giving thirty (30) days written notice.

4.- Confidential information

1. The Patient Organization will consider all information transmitted and/or generated in the performance of this Agreement, whether prior to or subsequent to the execution of this Agreement, to be Confidential Information.

2. For the purpose of this Agreement, Confidential Information means all information, whether written, oral or otherwise, supplied to or obtained by the Patient Organization, in the course of,

or as a result of the provision of the Services to Almirall including, but not limited to, proprietary, technical and business information relating to the Almirall or its affiliates, or any copy or part of such information.

3. The Patient Organization undertakes:

- not to disclose any Confidential Information to any third party without the prior written consent of the Almirall;
- to use or make copies of the Confidential Information only for the purpose of performing the agreed Services; and
- upon Almirall's written request, and in any event on termination of this Agreement according to clause 3, to deliver up or destroy any computer data, documents and all other tangible materials in its possession relating to or containing Confidential Information and certify in writing to Almirall, if requested, any such a request has been complied with.

4. The obligations set out in this Clause shall not apply to:

- Confidential Information which is in or becomes part of the public domain other than through the Patient Organization act or omission;
- Confidential Information which the Patient Organization can show by written evidence is received from a third party who is not under any obligation of confidence;
- Confidential Information which The Patient Organization can show by written evidence was in its possession at the time of disclosure by Almirall and which was not acquired directly or indirectly from the Almirall; and
- Confidential Information which the Patient Organization can show by written evidence is required to be disclosed as a matter of law or by a regulatory authority.

5. The obligations under this Clause in relation to disclosure of Confidential Information shall survive for a period of **ten (10) years** following such disclosure, notwithstanding the expiry or termination of this Agreement.

5.- Compliance with laws

1. The parties undertake to strictly comply with all applicable law, directive, regulations, instructions and other legal requirements in performing its obligations under this Agreement, including but not limited to those relating to personal data protection or promotion and publishing of medical products.

6.- Warranties

1.- The Patient Organization warrants that the provision of the Services is lawful and does not violate the rules contained in the advertising Law and in the specific legislation on pharmaceutical products, including its provisions relating to the promotion of medicines and medical devices through any means or channels used, including digital media or social networks. The Patient Organization warrants to refrain from conducting any type of action that could compromise or harm Almirall's interests or good name.

2.- The Patient Organization, for the sake of good transparency, guarantees that will publicly declare its status as Almirall's consultant while the provision of the Services takes place whenever it: (i) is involved in discussions about Almirall or its products, (ii) writes or speaks in public about a matter related to the works performed for Almirall or (iii) is participating with third parties on any other matter related to Almirall.

3. The Patient Organization declares to possess all the necessary approvals and permits for the provision of the Services, as required by the applicable laws and regulations including, but not limited to, the notification and / or respective authorization obtained from ethics committees, agencies, and / or other involved bodies, as the case may be.

7.- Ethical business practices

1.- The Patient Organization represents and warrants that none of its employees, agents, officers, or other members of its management are officials, officers, agents, or representatives of any government or political party having governmental authority to make or participate in any decisions regarding pharmaceutical products. The Patient Organization further represents and warrants that none of the individuals referred to in this paragraph have been or are in the process of being declared ineligible, debarred or suspended from conducting business with any department or agency of any government.

2.- The Patient Organization represents and warrants that neither the Patient Organization nor any of its employees, agents, officers, or other members of its management have business, economic, professional, personal or any other interest that would conflict, influence or affect in any manner the performance of obligations under this Agreement, including but not limited to: representations to or provision of services to other companies and/or shareholding in companies which are clients, services providers, competitors or potential investment targets of Almirall, which may constitute a conflict of interest. For further clarity, nothing in this paragraph is meant to restrict the activities of the the Patient Organization or to establish any exclusivity. However, the Patient Organization is obliged to inform Almirall immediately and in writing of any actual conflicts or potential conflicts of interest as soon as they arise. Almirall in its sole discretion shall decide if this constitutes a conflict under this Agreement and in such a case, Almirall may terminate the Agreement immediately upon written notice and pay for Services performed upon the moment of termination.

8.- Personal data protection

1.- For the performance of this Agreement, the Parties will comply with all the regulations on personal data protection that may be applicable.

2.- In case the provision of the Services implies the use by Almirall of personal data provided by the Patient Organization, the Patient Organization hereby agrees to obtain data of the relevant individuals in compliance with the applicable privacy regulations for the purposes that Almirall may be authorized for the processing and transferring and/or communicating such personal data and information to (a) any Almirall affiliates, (b) any third party providing data processing services to Almirall and/or its affiliates, and/or (c) to the EFPIA and/or to the local Pharmaceutical Industry Association, its contractors and sub-contractors as may be required, for the purposes of fulfilling with any obligations under this Agreement and those arising from any laws applicable to the activity of Almirall, as well as those arising from the deontological codes and standards of the pharmaceutical industry, either international or local. In case of international transfers, appropriate safeguards shall be taken in accordance with the applicable regulations. Data will be processed during the life of this agreement as well as during the necessary term to comply with legal obligations.

3.- *Representatives Personal Data*- The Parties to this Agreement will inform the individuals who act on their behalf (*representatives*) that the personal data reflected in this Agreement may be incorporated into their respective records. Personal data will be processed for managing this agreement and will be kept during its validity as well as during the additional time that is necessary in order to comply with the corresponding legal obligations. The Parties expressly acknowledge and accept that the personal data related to this contract may be transferred to their affiliated companies for the correct management of the contractual relationship. The representatives may exercise their rights in the terms provided in the data protection regulations by contacting the address provided by each Party in this Agreement. Likewise, they may lodge a complaint at the corresponding Supervisory Authority for any claim arising from the processing of their personal data.

9.- Intellectual property rights

1.- The Patient Organization assigns to Almirall any rights (including but not limited to intellectual property rights and image rights) on the reports, materials, and pictures or

photographs developed or obtained as a consequence of rendering the Services (including any such rights resulting from the Presentation, if any), exclusively and irrevocably, and without any additional compensation to the price of the Services, for an indefinite period and without territorial limitation, Almirall being entitled to assign any said rights to third parties. The Patient Organization will be able to use the Presentation and issue publications, subject to the prior written authorization of Almirall. If applicable, the Patient Organization will ensure that any images, including photographs or digital likeness, taken or acquired by the Patient Organization in the context of the Services have been or shall be duly obtained with the prior written informed and explicit consent of the relevant individual, which consent shall include the right for the Patient Organization to assign them to Almirall and/or its designees for the purposes to distribute, publish or otherwise use such images in its discretion, worldwide and in perpetuity.

2.- The Patient Organization hereby represents that the use of the above referred materials by Almirall and or its designees does not violate any legal provision, contract, rights of intellectual or industrial property, honour, privacy, own image or any other rights or property of third parties, nor in any way constitute unfair competition.

10.- Transfer of value.

The Patient Organization acknowledges that Almirall is required by the EFPIA Disclosure Code and, as the case may be, by the Code of the local Pharmaceutical Industry Association (the “Codes”), to document and publicly disclose certain transfers of value (“ToV”) made to healthcare professionals or healthcare organisations, including any information about payments or other ToV provided under and/or in connection to this Agreement.

11.- Assignment

The Patient Organization will not assign, transfer, sub-contract or otherwise invest any third parties, totally or partially, with the benefits or burdens of this Agreement without the prior written consent of Almirall. Almirall shall be free to assign, transfer, sub-contract or otherwise invest any affiliates or third parties, totally or partially, with the benefits or burdens of this Agreement without the prior written consent of Advisor.

12.- Amendments. Sole agreement

No changes may be made to this Agreement except by written agreement of both parties. This Agreement supersedes all prior written agreement between the parties regarding the subject matter hereof.




13.- Independent Contractors

The Patient Organization’s relationship with Almirall under this Agreement shall be that of an independent contractor, and nothing in this Agreement or the arrangements for which it is made shall constitute the Patient Organization or any of its agents or representatives as an employee, partner, representative, agent or servant of Almirall.

14.- Governing law and jurisdiction

In the event that any dispute arises with respect to the validity, construction or performance of this Agreement, the parties agree to submit such dispute to the jurisdiction and competence of the Courts of Copenhagen, Denmark waiving any other jurisdiction applicable. All questions with respect of the construction of this Agreement and the rights and liabilities of the parties hereunder, shall be determined in accordance with the applicable provisions of the Danish law.

IN WITNESS WHEREOF, the parties have executed this Agreement as of the day and year first above written.

Almirall Aps	<p>Place and Date: Denmark 21/10/2025 10:07 CEST</p> <p>Firmado por:  4911345A340040C...</p> <p>Ivan Seguro Noguerras, Associate Director Finance</p> <p>Place and Date: Denmark 21/10/2025 10:53 CEST</p> <p>Signed by:  A1A83F185B6041D...</p> <p>Kristian Gaarn du Jardin, Medical Director</p>
Atopisk Eksem Forening / Eksemforeningen	<p>Place and Date: Denmark 21/10/2025 13:38 MDT</p> <p>Signed by:  5A0F358E642D4BA...</p> <p>Anne Skov Vastrup, Forperson</p>